| Title |
Levamisole in Dermatology
|
|---|---|
| Published in |
American Journal of Clinical Dermatology, August 2012
|
| DOI | 10.2165/00128071-200405020-00004 |
| Pubmed ID | |
| Authors |
Noah Scheinfeld, Joshua D. Rosenberg, Jeffrey M. Weinberg |
| Abstract |
Levamisole, an anthelmintic agent with a wide range of immunomodulatory actions, has been used successfully as monotherapy and an adjunct to treatment in a variety of diseases. Since 1990, combination therapy of levamisole and fluorouracil has played an important role in the treatment of resected Dukes stage C adenocarcinoma of the colon. Because of its immunomodulating effects levamisole has been used in a wide range of diseases with and without success. In dermatologic disease levamisole has been successfully used in the treatment of parasitic, viral and bacterial infections including leprosy, collagen vascular diseases, inflammatory skin diseases and children with impaired immune a variety of reasons. It has also been used in combination with other drugs for treating a number of dermatologic disorders, e.g. in combination with cimetidine for treating recalcitrant warts, with prednisolone for treating lichen planus, erythema multiforme and aphthous ulcers of the mouth. Adverse affects of levamisole are mild and infrequent and include rash, nausea, abdominal cramps, taste alteration, alopecia, arthralgia, and a flu-like syndrome. It can rarely cause agranulocytosis. More studies need to be undertaken to study the full potential of levamisole in dermatologic diseases. |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 3 | 4% |
| Unknown | 71 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 12% |
| Student > Bachelor | 9 | 12% |
| Student > Master | 7 | 9% |
| Other | 5 | 7% |
| Student > Postgraduate | 5 | 7% |
| Other | 13 | 18% |
| Unknown | 26 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Environmental Science | 2 | 3% |
| Chemistry | 2 | 3% |
| Other | 4 | 5% |
| Unknown | 27 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2020.
All research outputs
#8,534,976
of 25,374,647 outputs
Outputs from American Journal of Clinical Dermatology
#568
of 1,066 outputs
Outputs of similar age
#63,545
of 186,131 outputs
Outputs of similar age from American Journal of Clinical Dermatology
#140
of 281 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,066 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.5. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,131 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 281 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.